Last updated on October 2016

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations


Brief description of study

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Detailed Study Description

The purpose of this study is to evaluate the overall response rate (ORR) of INCB054828 as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.

Clinical Study Identifier: TX145643

Contact Investigators or Research Sites near you

Start Over

Incyte Corporation Call Center

Research Center
Salt Lake City, UT USA
  Connect »

Incyte Corporation Call Center

Research Center
Temple, TX USA
  Connect »

Incyte Corporation Call Center

Research Center
Tacoma, WA USA
  Connect »

Incyte Corporation Call Center

Research Center
Myrtle Beach, SC USA
  Connect »

Incyte Corporation Call Center

Research Center
Omaha, NE USA
  Connect »

Incyte Corporation Call Center

Research Center
Las Vegas, NV USA
  Connect »